Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday, Briefing.com reports. Several other equities analysts have also issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of […]
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.72 and last traded at $24.89, with a volume of 549844 shares traded. The stock had previously closed at $24.00. Analyst Ratings Changes CBAY has been the subject […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) has received an average rating of “Buy” from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target […]
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Twelve analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […]
Emerald Mutual Fund Advisers Trust acquired a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 809,738 shares of the biopharmaceutical company’s stock, valued at approximately $12,073,000. Emerald Mutual Fund Advisers […]